chloroquine and derivatives - versus placebo - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.89 [0.55, 1.46]< 10%4 studies (4/-)67.5 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.80 [0.62, 5.21]< 10%1 study (1/-)13.9 %some concernnot evaluable moderateimportant-
clinical improvement 1.13 [0.86, 1.48]> 11%2 studies (2/-)81.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.36 [0.87, 2.11]> 10%1 study (1/-)91.0 %some concernnot evaluable moderateimportant-
death or ventilation 1.12 [0.45, 2.79]< 10%1 study (1/-)40.4 %some concernnot evaluable moderateimportant-

safety endpoints 00

adverse events 1.71 [0.92, 3.17]< 164%3 studies (3/-)4.6 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.